Pyxis Oncology (NASDAQ:PYXS) Stock Price Expected to Rise, Royal Bank Of Canada Analyst Says

Pyxis Oncology (NASDAQ:PYXS) had its target price lifted by equities research analysts at Royal Bank Of Canada from $6.00 to $7.00 in a note issued to investors on Friday, Benzinga reports. The firm presently has an “outperform” rating on the stock. Royal Bank Of Canada‘s price target suggests a potential upside of 315.43% from the company’s previous close.

Several other analysts also recently commented on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Pyxis Oncology in a research report on Friday, September 25th. Wells Fargo & Company lifted their target price on shares of Pyxis Oncology from $12.00 to $19.00 and gave the stock an “overweight” rating in a report on Wednesday, September 9th. Wedbush dropped their target price on shares of Pyxis Oncology from $8.00 to $7.00 and set an “outperform” rating on the stock in a research note on Friday. HC Wainwright increased their price target on shares of Pyxis Oncology from $7.00 to $8.00 and gave the company a “buy” rating in a report on Thursday, September 10th. Finally, Stifel Nicolaus set a $5.00 price target on shares of Pyxis Oncology in a research report on Thursday. Seven research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $8.71.

Pyxis Oncology Stock Up 4.7%

Shares of NASDAQ:PYXS traded up $0.07 during trading on Friday, hitting $1.69. The stock had a trading volume of 303,031 shares, compared to its average volume of 904,633. The firm’s fifty day moving average is $2.54 and its 200 day moving average is $2.16. The company has a market capitalization of $140.54 million, a PE ratio of -1.20 and a beta of 1.41. Pyxis Oncology has a 12 month low of $1.03 and a 12 month high of $5.55.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.27) by $0.03. Equities research analysts expect that Pyxis Oncology will post -1.21 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Commonwealth Equity Services LLC lifted its position in Pyxis Oncology by 14.8% during the third quarter. Commonwealth Equity Services LLC now owns 48,750 shares of the company’s stock valued at $114,000 after purchasing an additional 6,295 shares during the period. T3 Companies LLC purchased a new stake in Pyxis Oncology in the third quarter worth approximately $61,000. Finally, Renaissance Technologies LLC grew its position in Pyxis Oncology by 22.0% in the 1st quarter. Renaissance Technologies LLC now owns 888,680 shares of the company’s stock worth $1,297,000 after purchasing an additional 160,300 shares during the period. 39.07% of the stock is owned by hedge funds and other institutional investors.

Pyxis Oncology Company Profile

Pyxis Oncology, Inc is a clinical-stage biotechnology company focused on developing antibody-based therapies for the treatment of cancer. The company aims to address limitations of existing cancer treatments by designing therapeutics intended to selectively target tumors and activate the immune system while minimizing effects on healthy tissue.

Pyxis Oncology’s pipeline includes antibody-drug conjugates and immunotherapies designed to act on targets in the tumor microenvironment. Its lead programs have included PYX-201, an antibody-drug conjugate intended to deliver a cytotoxic payload to tumors expressing the fibronectin extra domain-B target, and other investigational antibody-based programs directed at immune-suppressive pathways.